Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing

被引:23
作者
Hehir-Kwa, Jayne Y. [1 ]
Koudijs, Marco J. [1 ,2 ]
Verwiel, Eugene T. P. [1 ]
Kester, Lennart A. [1 ]
van Tuil, Marc [1 ]
Strengman, Eric [1 ]
Buijs, Arjan [2 ]
Kranendonk, Mariette E. G. [1 ]
Hiemcke-Jiwa, Laura S. [1 ]
de Haas, Valerie [1 ]
van de Geer, Ellen [1 ]
de Leng, Wendy [3 ]
van der Lugt, Jasper [1 ]
Lijnzaad, Philip [1 ]
Holstege, Frank C. P. [1 ]
Kemmeren, Patrick [1 ]
Tops, Bastiaan B. J. [1 ]
机构
[1] Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Labs Pharm & Biomed Genet, Sect Genome Diagnost, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Labs Pharm & Biomed Genet, Sect Pathol, Utrecht, Netherlands
关键词
MINIMAL RESIDUAL DISEASE; MESOBLASTIC NEPHROMA; GENOMIC ALTERATIONS; TRANSLOCATIONS; LEUKEMIA; REARRANGEMENTS;
D O I
10.1200/PO.20.00504
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Gene fusions play a significant role in cancer etiology, making their detection crucial for accurate diagnosis, prognosis, and determining therapeutic targets. Current diagnostic methods largely focus on either targeted or low-resolution genome-wide techniques, which may be unable to capture rare events or both fusion partners. We investigate if RNA sequencing can overcome current limitations with traditional diagnostic techniques to identify gene fusion events. METHODS We first performed RNA sequencing on a validation cohort of 24 samples with a known gene fusion event, after which a prospective pan-pediatric cancer cohort (n = 244) was tested by RNA sequencing in parallel to existing diagnostic procedures. This cohort included hematologic malignancies, tumors of the CNS, solid tumors, and suspected neoplastic samples. All samples were processed in the routine diagnostic workflow and analyzed for gene fusions using standard-of-care methods and RNA sequencing. RESULTS We identified a clinically relevant gene fusion in 83 of 244 cases in the prospective cohort. Sixty fusions were detected by both routine diagnostic techniques and RNA sequencing, and one fusion was detected only in routine diagnostics, but an additional 24 fusions were detected solely by RNA sequencing. RNA sequencing, therefore, increased the diagnostic yield by 38%-39%. In addition, RNA sequencing identified both gene partners involved in the gene fusion, in contrast to most routine techniques. For two patients, the newly identified fusion by RNA sequencing resulted in treatment with targeted agents. CONCLUSION We show that RNA sequencing is sufficiently robust for gene fusion detection in routine diagnostics of childhood cancers and can make a difference in treatment decisions. (C) 2022 by American Society of Clinical Oncology
引用
收藏
页数:12
相关论文
共 49 条
  • [1] Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
    Akasaka, Takashi
    Balasas, Theodore
    Russell, Lisa J.
    Sugimoto, Kei-ji
    Majid, Aneela
    Walewska, Renata
    Karran, E. Loraine
    Brown, David G.
    Cain, Kelvin
    Harder, Lana
    Gesk, Stefan
    Martin-Subero, Jose Ignacio
    Atherton, Mark G.
    Brueggemann, Monika
    Calasanz, Maria Jose
    Davies, Teresa
    Haas, Oskar A.
    Hagemeijer, Anne
    Kempski, Helena
    Lessard, Michel
    Lillington, Debra M.
    Moore, Sarah
    Nguyen-Khac, Florence
    Radford-Weiss, Isabelle
    Schoch, Claudia
    Struski, Stephanie
    Talley, Polly
    Welham, Melanie J.
    Worley, Helen
    Strefford, Jon C.
    Harrison, Christine J.
    Siebert, Reiner
    Dyer, Martin J. S.
    [J]. BLOOD, 2007, 109 (08) : 3451 - 3461
  • [2] Promiscuous genes involved in recurrent chromosomal translocations in soft tissue tumours
    Antonescu, Cristina R.
    Dal Cin, Paola
    [J]. PATHOLOGY, 2014, 46 (02) : 105 - 112
  • [3] A novel real-time RT-PCR assay for quantification of OTT-MAL fusion transcript reliable for diagnosis of t(1;22) and minimal residual disease (MRD) detection
    Ballerini, P
    Blaise, A
    Mercher, T
    Pellegrino, B
    Perot, C
    van den Akker, J
    Gatbois, E
    Adam, M
    Douay, L
    Berger, R
    Bernard, O
    Landman-Parker, J
    [J]. LEUKEMIA, 2003, 17 (06) : 1193 - 1196
  • [4] THE HUMAN C-MYC-ONCOGENE - STRUCTURAL CONSEQUENCES OF TRANSLOCATION INTO THE IGH LOCUS IN BURKITT-LYMPHOMA
    BATTEY, J
    MOULDING, C
    TAUB, R
    MURPHY, W
    STEWART, T
    POTTER, H
    LENOIR, G
    LEDER, P
    [J]. CELL, 1983, 34 (03) : 779 - 787
  • [5] A 3RD TAL-1 PROMOTER IS SPECIFICALLY USED IN HUMAN T-CELL LEUKEMIAS
    BERNARD, O
    AZOGUI, O
    LECOINTE, N
    MUGNERET, F
    BERGER, R
    LARSEN, CJ
    MATHIEUMAHUL, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (04) : 919 - 925
  • [6] Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia
    Blackburn, Patrick R.
    Smadbeck, James B.
    Znoyko, Iya
    Webley, Matthew R.
    Pitel, Beth A.
    Vasmatzis, George
    Xu, Xinjie
    Greipp, Patricia T.
    Hoppman, Nicole L.
    Ketterling, Rhett P.
    Baughn, Linda B.
    Lindsey, Kathryn G.
    Schandl, Cynthia A.
    Wolff, Daynna J.
    Peterson, Jess F.
    [J]. GENES CHROMOSOMES & CANCER, 2020, 59 (07) : 422 - 427
  • [7] Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
    Botton, Thomas
    Talevich, Eric
    Mishra, Vivek Kumar
    Zhang, Tongwu
    Shain, A. Hunter
    Berquet, Celine
    Gagnon, Alexander
    Judson, Robert L.
    Ballotti, Robert
    Ribas, Antoni
    Herlyn, Meenhard
    Rocchi, Stephane
    Brown, Kevin M.
    Hayward, Nicholas K.
    Yeh, Iwei
    Bastian, Boris C.
    [J]. CELL REPORTS, 2019, 29 (03): : 573 - +
  • [8] DNA methylation-based classification of central nervous system tumours
    Capper, David
    Jones, David T. W.
    Sill, Martin
    Hovestadt, Volker
    Schrimpf, Daniel
    Sturm, Dominik
    Koelsche, Christian
    Sahm, Felix
    Chavez, Lukas
    Reuss, David E.
    Kratz, Annekathrin
    Wefers, Annika K.
    Huang, Kristin
    Pajtler, Kristian W.
    Schweizer, Leonille
    Stichel, Damian
    Olar, Adriana
    Engel, Nils W.
    Lindenberg, Kerstin
    Harter, Patrick N.
    Braczynski, Anne K.
    Plate, Karl H.
    Dohmen, Hildegard
    Garvalov, Boyan K.
    Coras, Roland
    Hoelsken, Annett
    Hewer, Ekkehard
    Bewerunge-Hudler, Melanie
    Schick, Matthias
    Fischer, Roger
    Beschorner, Rudi
    Schittenhelm, Jens
    Staszewski, Ori
    Wani, Khalida
    Varlet, Pascale
    Pages, Melanie
    Temming, Petra
    Lohmann, Dietmar
    Selt, Florian
    Witt, Hendrik
    Milde, Till
    Witt, Olaf
    Aronica, Eleonora
    Giangaspero, Felice
    Rushing, Elisabeth
    Scheurlen, Wolfram
    Geisenberger, Christoph
    Rodriguez, Fausto J.
    Becker, Albert
    Preusser, Matthias
    [J]. NATURE, 2018, 555 (7697) : 469 - +
  • [9] ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
    Childress, Merrida A.
    Himmelberg, Stephen M.
    Chen, Huiqin
    Deng, Wanleng
    Davies, Michael A.
    Lovly, Christine M.
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (11) : 1724 - 1736
  • [10] Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
    Church, Alanna J.
    Calicchio, Monica L.
    Nardi, Valentina
    Skalova, Alena
    Pinto, Andre
    Dillon, Deborah A.
    Gomez-Fernandez, Carmen R.
    Manoj, Namitha
    Haimes, Josh D.
    Stahl, Joshua A.
    Dela Cruz, Filemon S.
    Tannenbaum-Dvir, Sarah
    Glade-Bender, Julia L.
    Kung, Andrew L.
    DuBois, Steven G.
    Kozakewich, Harry P.
    Janeway, Katherine A.
    Perez-Atayde, Antonio R.
    Harris, Marian H.
    [J]. MODERN PATHOLOGY, 2018, 31 (03) : 463 - 473